Addition of navitoclax to ruxolitinib for patients with myelofibrosis with progression or suboptimal response
Naveen Pemmaraju(The University of Texas MD Anderson Cancer Center), Jacqueline S. Garcia(Dana-Farber Cancer Institute), Rami S. Komrokji(Moffitt Cancer Center), David Lavie(Hadassah Medical Center), Jason G. Harb(AbbVie (United States)), Claire Harrison(Guy's and St Thomas' NHS Foundation Trust), Akihiro Tomita(Nagoya University), Andrew C. Perkins(Monash Medical Centre), Rosa Ayala(Hospital Universitario 12 De Octubre), Akshanth R. Polepally(AbbVie (United States)), Tim C. P. Somervaille(University of Manchester), Jalaja Potluri(AbbVie (United States)), Qin Qin(Soochow University), Feng Yang(Yunnan Normal University), Francesca Palandri(Istituto Oncologico Romagnolo)
Cited by 12
Related Papers
Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study
|Cancer Discovery|2018|570
Targeting the RNA m6A Reader YTHDF2 Selectively Compromises Cancer Stem Cells in Acute Myeloid Leukemia
|Cell stem cell|2019|552
Ibrutinib and Venetoclax for First-Line Treatment of CLL
|New England Journal of Medicine|2019|502